Aravax
Australia - MelbourneBiotechnology
Focus: Aravax is an Australian biotech founded in 2015 focused on allergy immunotherapy, currently advancing a single Phase 2 program for peanut allergy. The company operates as a pre-revenue, clinical-stage biotech with minimal public scale data.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Aravax
AI assessmentNot HiringNo open roles listed right now. Follow Aravax to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PVX-108
Peanut AllergyClinical Trials (1)
NCT05621317A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Phase 2Help build intelligence for Aravax
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.